Sun Yat-sen University Cancer Center: Gastrointestinal and Nasopharyngeal Teams

A public cancer hospital and research institute in Guangzhou

Founded in 1964, the public specialist center brings clinical care, teaching and research together. An institutional account authored by Xu Ruihua in 2023 describes disease-specific multidisciplinary teams linking surgical, medical and radiation oncology. Principal experts and treating professors coordinate work around a cancer type, supported by clinical-research quality monitoring.

The center placed second for oncology in the Fudan project's 2023 national specialty reputation list. This historical department-level reference is not a current ranking of individual doctors or of its gastrointestinal and nasopharyngeal programs. Those programs should be considered through their own clinical and research focus.

Xu Ruihua and gastrointestinal oncology research leadership

Xu Ruihua's documented clinical field covers esophageal, gastric and colorectal cancers. In November 2025, Sun Yat-sen University announced his election to the Chinese Academy of Engineering and identified him as director of the Huanan Malignant Tumor National Key Laboratory. The same announcement credits him as first contributor to two National Science and Technology Progress Second Prizes.

His personal honors also include the He Liang He Li science-and-technology award, Tan Jiazhen Clinical Medicine Award and Wu Jieping medical innovation recognition. Separately, a January 2025 university feature recorded his inclusion in Cell Press's 2024 “50 Scientists That Inspire” interview series. That was an editor-nominated scientific recognition, rather than a ranking of clinical services.

The January feature described Xu as hospital president, research-institute director and a medical-oncology professor at that time. It also explained his emphasis on connecting clinical questions with laboratory investigation and collaboration across surgery and radiotherapy. These different roles provide context for a gastrointestinal oncology enquiry; a research-author listing alone does not confirm who will assess a new case.

Colorectal resistance and biomarker-selected gastric treatment

CAPability-01 addressed an immunotherapy-resistance question in microsatellite-stable or mismatch-repair-proficient colorectal cancer. The national multicenter study was randomized, two-arm and phase II. It investigated an anti-angiogenic agent and a histone-deacetylase inhibitor combined with immunotherapy—not simply a checkpoint inhibitor added to standard chemotherapy. The university interview describes work moving from biological investigation to a defined clinical study.

For patients, the distinction between a study population and an individual treatment decision is essential. The name of a trial does not establish that someone with the same broad cancer diagnosis is eligible for its regimen or a future study. Existing molecular findings, previous treatment and the question for another opinion can be reviewed by the relevant clinical team.

GLOW examined a different population: CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma. Published in Nature Medicine in July 2023, it was an international multicenter, randomized, placebo-controlled phase III study led by Xu as global principal investigator. It compared the targeted antibody zolbetuximab plus chemotherapy with placebo plus the same chemotherapy backbone.

Its research endpoints included progression-free survival, overall survival and safety. This is a concrete example of molecularly selected gastrointestinal research. It does not establish the appropriate medicine for every gastric cancer patient, nor confirm present access or predict an individual result. A treatment discussion must distinguish tumor testing, trial evidence and the options actually available for the case.

Ma Jun, Sun Ying and Tang Linglong: nasopharyngeal radiotherapy

The nasopharyngeal program has a different emphasis: refining radiation treatment after induction chemotherapy. In February 2025, Ma Jun, Sun Ying and Tang Linglong's team reported a study in CA: A Cancer Journal for Clinicians. Ma, Sun, Tang, Guo Rui and Xie Fangyun were corresponding authors.

The multicenter, open-label, non-inferiority randomized phase III trial compared radiation volumes based on the tumor's extent after induction chemotherapy with volumes based on its original extent. It investigated tumor control alongside toxicity and quality of life. Reducing normal-tissue exposure was a research objective, not a recommendation that every patient receive a smaller radiation field.

The university identifies Ma as a Chinese Academy of Sciences academician and credits his wider nasopharyngeal research with three National Science and Technology Progress Second Prizes. These career achievements should not be attributed solely to this one trial. The clinical focus is the balance between disease control and treatment burden, with planning decisions belonging to the treating radiation-oncology team.

Laboratory mechanisms and international translational collaboration

Xu and external collaborator Zhao Xia of Army Medical University also investigated the gut microbiome. Their July 2025 Cancer Cell report connected human stool-metagenomic associations with experiments in germ-free and other mouse models. The work examined Alistipes finegoldii and an immune-cell-recruitment mechanism involving its LIPOAF protein. Human association and animal mechanism are different types of evidence; this is not a recommendation to take probiotics or living bacteria during cancer treatment.

Another research direction concerns Epstein–Barr virus. Zeng Musheng, identified in November 2025 as the center's deputy director and deputy hospital head, was elected to the Chinese Academy of Sciences. His work on viral receptors and sequential entry informed candidate-vaccine research; the announcement credits him as first contributor to a 2023 National Natural Science Second Prize. Candidate research does not establish an approved vaccine service.

A February 2025 Cancer Cell commentary discussed a Global Cancer Translational Research Alliance. Xu was final corresponding author, with Luo Huiyan and Lu Yunxin as co-first authors. External collaborators included Kohei Shitara of Japan's National Cancer Center and Heinz-Josef Lenz of the University of Southern California. Its themes included ethics, data and sample platforms, and clinical–laboratory training. This was a collaboration commentary, not a patient-recruitment announcement.

Preparing a focused gastrointestinal or nasopharyngeal enquiry

Start with the question another opinion should resolve, rather than a requested drug or the name of a prize-winning researcher. For gastrointestinal cancer, identify the diagnosis already recorded and whether the unresolved question concerns a proposed operation, systemic treatment or molecular findings. For nasopharyngeal cancer, state whether the enquiry concerns an initial plan or a review of treatment already received.

Ask which existing records require translation, which team should assess them and which campus would handle any accepted assessment. Confirm language support and the written scope before arranging travel. Publication of a study does not confirm an appointment, trial place or treatment availability. Urgent or worsening symptoms require local medical assessment instead of waiting for overseas arrangements.

Cancer care in China for international patients

Independent coordination for an oncology enquiry

ChinaSpecialistCare can help organise records, clarify the enquiry and coordinate assessment arrangements after hospital acceptance. We are independent of the hospital and cannot guarantee a named clinician, trial place or treatment outcome. An initial enquiry is free; an optional proxy consultation is not required to make that enquiry.